A study to find the effect of Tofacitinib film forming lotion compared to mometasone solution in baldhead patients
- Conditions
- Health Condition 1: L639- Alopecia areata, unspecified
- Registration Number
- CTRI/2024/01/061349
- Lead Sponsor
- Hetero Healthcare Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients aged 18 – 50 years of either gender with clinical diagnosis of alopecia areata.
2. Patients in good health with no evidence of systemic illness.
3. Willing to report response to treatment as per protocol during the study period.
4. Willing to give written informed consent.
1. Any subject who is currently experiencing significant spontaneous regrowth of terminal hair.
2. Any subject treated with a topical, intralesional or systemic agent likely to cause regrowth in alopecia areata within the past month.
3. Patients who concomitantly using systemic drugs (steroids, cytotoxic agents (methotrexate, azathioprine), vasodilators, antihypertensive agents, anticonvulsant drugs, beta-adrenergic receptor blockers, diuretics, spironolactone, diazoxide, cyclosporine, or ketoconazole.
4. Patients with H / O Tuberculosis or any serious illness.
5. H/ o hypersensitivity to study medication.
6. Participating in other clinical trials
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Change in SALT score <br/ ><br>- Percent scalp hair regrowth based on extent of absolute hair loss (percent scalp hair regrowth based on extent of absolute hair loss. (percent scalp hair regrowth based on SALT score).Timepoint: Week 4, week 8 and week 12 (end of study)
- Secondary Outcome Measures
Name Time Method Treatment Emergent Adverse Events (TEAEs)Timepoint: Week 4, Week 8 and Week 12